Pitavastatin

Evidence Level: L5

Predicted Indications: 4

Pitavastatin

Pharmacist Assessment Report

Pitavastatin: From Familial Combined Hyperlipidaemia to Cholesterol-Ester Transfer Protein Deficiency

One-Sentence Summary

Pitavastatin is a statin (cholesterol-lowering drug). It is marketed in this country with 20 valid licences. The TxGNN model predicts it may be effective for cholesterol-ester transfer protein (CETP) deficiency, with a very high score. However, no clinical trials and no publications in the data compiled for this report support this specific pairing, so the prediction is model-only.

Quick Overview

Item	Content
Original Indication	Familial combined hyperlipidaemia (relation recorded in the knowledge graph; the licence records contain no approved-indication text)
Predicted New Indication	Cholesterol-ester transfer protein deficiency
TxGNN Prediction Score	0.9998
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the compiled data. Pitavastatin belongs to the statin class, which lowers LDL cholesterol by inhibiting HMG-CoA reductase. Its recorded link is to inherited lipid disorders, so a connection to another inherited lipid-metabolism condition is biologically adjacent.

CETP deficiency is a genetic condition marked by high HDL cholesterol and altered lipoprotein metabolism. The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence or a demonstrated therapeutic need. CETP deficiency is generally not associated with raised cardiovascular risk that would call for statin treatment, and the mechanistic link is therefore weak. No trial or publication supports the pairing.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

The compiled data lists at least 20 valid licences for pitavastatin-containing products, and the list may be partial. None of the records include approved-indication text. Several products are fixed-dose combinations, so the table below shows only products that appear to be single-ingredient pitavastatin.

Authorization Number	Product Name	Dosage Form	Manufacturer
126527	Livastat 4 Tablet	Strip of 10 tablets	Novazen Pharmaceuticals
174138	Pivasta 4 Tablet	Strip of 10 tablets	Zydus Cadila
178717	Pitava 1mg Tablet	Strip of 10 tablets	Zydus Cadila
179727	Ptvs 2mg Tablet	Strip of 10 tablets	Druto Laboratories
64399	Diabastat 4 Tablet	Strip of 10 tablets	NYG Pharmaceuticals Pvt Ltd

Safety Considerations

Relations recorded in the knowledge graph (not label text): The following conditions are linked to pitavastatin as contraindications: liver disease, gallbladder disease, hypothyroidism (including myxedema and congenital hypothyroidism), myopathy and other muscle diseases, familial periodic paralysis, hypotensive disorder, rhabdomyolysis, nodular fasciitis, impaired renal function, and injury.
Drug interactions: 86 interactions are recorded in total. The one rated Major is erythromycin. Examples rated Moderate include rosuvastatin, simvastatin, cobicistat, eltrombopag, metronidazole, chloroquine, hydroxychloroquine, naltrexone and ethanol. Warfarin and dicoumarol are rated Minor.

Package insert warnings and contraindications were not available. Please refer to the package insert for the full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a high model score. There are no trials or publications for this disease, and the mechanistic link is weak because CETP deficiency does not usually call for statin therapy.

To proceed, the following is needed:

Evidence that CETP deficiency carries a clinical risk or lipid problem that a statin would address
Detailed mechanism-of-action data for pitavastatin
Package insert warnings and contraindications from the Indian licence holders
Genetic and clinical validation, such as a pilot study or a review of existing patient cohorts

Note on other candidates: Among the other predictions for this drug, HIV infectious disease has substantial supporting evidence, including a published randomised trial (REPRIEVE) and several follow-up studies. That benefit is primary prevention of cardiovascular disease in people with HIV, not treatment of the infection itself. It could be evaluated as a separate report, with attention to interactions with antiretrovirals.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.